Bioscience

Provista Life Sciences provides independent validation of Radient Pharmaceuticals’ Onko-Sure cancer test

May 4, 2010

By Flinn Foundation

[Source: Marketwire] – Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation announced today diagnostics development and commercialization firm Provista Life Sciences LLC (PLS) has independently validated Radient Pharmaceuticals’ Onko-Sure in vitro diagnostic (IVD) cancer test as a potential screening tool for breast cancer detection.

For more information: Provista Life Sciences Provides Independent Validation of Radient Pharmaceuticals’ Onko-Sure(TM) Cancer Test